Screener
Protagonist Therapeutics PTGX Business Segments — Employee Expense Benefit Related To Development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept ptgx:EmployeeExpenseBenefitRelatedToDevelopment.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Development department expense (1)(2) | (14,432) | (15,504) | (31,905) | (28,409) |
| General and administrative expenses (1) | (5,745) | (5,890) | (11,440) | (11,425) |
| Employee wages and benefits - discovery (2) | (2,668) | (2,188) | (5,816) | (4,515) |
| Employee wages and benefits - development (2) | (4,949) | (4,658) | (10,901) | (10,142) |
| Employee wages and benefits - general and administrative | (4,357) | (3,483) | (9,080) | (7,315) |
| Stock-based compensation expense | (14,037) | (10,912) | (28,556) | (24,714) |
| Other segment items (3) | (81) | 36 | (28) | 118 |
| Interest income | 6,429 | 7,406 | 12,305 | 14,979 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's business segments — employee expense benefit related to development?
- Protagonist Therapeutics (PTGX) reported business segments — employee expense benefit related to development of $4.95M in Q2 2026.
- How has Protagonist Therapeutics's business segments — employee expense benefit related to development changed year-over-year?
- Protagonist Therapeutics's business segments — employee expense benefit related to development increased by 6.2% year-over-year, from $4.66M to $4.95M.
- What is the long-term trend for Protagonist Therapeutics's business segments — employee expense benefit related to development?
- Over 3 years (2022 to 2025), Protagonist Therapeutics's business segments — employee expense benefit related to development has grown at a 3.5% compound annual growth rate (CAGR), from $19.28M to $21.39M.
- What does business segments — employee expense benefit related to development mean?
- This captures the cash-based compensation and benefits for staff focused on clinical development, including clinical operations, regulatory affairs, and medical affairs. It serves as a proxy for the company's investment in the human resources necessary to execute clinical trials and navigate regulatory pathways. This is a key indicator of the company's commitment to advancing its pipeline toward market approval.
Ask your AI about Protagonist Therapeutics's business segments — employee expense benefit related to development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude